The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts

Bandita Adhikari, Jie Li, Michael G. Brandel, Diahnn Futalan, Johnny Akers, Timothy Deming, Clark C. Chen, Bob S. Carter

Research output: Contribution to journalArticlepeer-review

Abstract

The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB). For example, only a fraction of temozolomide (TMZ) administered systemically is available for therapeutic effect because of the BBB and the instability of TMZ under physiologic conditions. A novel approach to overcome this obstacle is to bypass the BBB and locally deliver chemotherapeutic agents directly to the tumor mass. We have explored the loading of TMZ into a novel hydrogel matrix, which can be delivered in liquid form and then solidifies in situ and releases chemotherapy as the matrix dissolves. Here, we tested the effect of amphiphilic diblock copolypeptide hydrogels (DCHs) of 180-poly-lysine and 20-poly-leucine (K180L20) on TMZ using Glioblastoma models. In both the in vitro model, which involved treatment of a human glioblastoma GSC line suspended as neurospheres, and in vivo using an orthotopic glioma xenograft mouse model, we found that K180L20 could safely enhance the efficacy of TMZ. This technique may offer the opportunity to ‘coat’ the inner lining of the cavity following glioma resection with a slow-release TMZ and potentially decrease recurrence. Future studies in larger animals are needed to delineate this effect.

Original languageEnglish (US)
Pages (from-to)288-292
Number of pages5
JournalJournal of Clinical Neuroscience
Volume45
DOIs
StatePublished - Nov 2017

Keywords

  • Glioma
  • Hydrogel
  • TMZ

Fingerprint Dive into the research topics of 'The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts'. Together they form a unique fingerprint.

Cite this